Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8215 results

  1. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  3. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  4. AI software for electroencephalogram (EEG) interpretation in epilepsy

    In development Reference number: GID-HTE10086 Expected publication date: TBC

    Health technology evaluations
    In development

  5. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  6. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 3 February 2026.

    Technology appraisal guidance
    In consultation

  7. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  8. Prognostic tests for multiple myeloma

    Awaiting development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  10. Blood transfusion - Tranexamic acid (update)

    In development Reference number: GID-NG10441 Expected publication date:  26 February 2026

    NICE guideline
    In development

  11. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  12. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  13. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  02 December 2026

    Quality standard
    In development

  14. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development